MedTrace Logo

Reducing Transition Drug Risk

NCT00370916 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 612

Last updated 2015-04-07

No results posted yet for this study

Summary

Patient transfer between sites of care is regular practice during an episode of care in our current health care system. Yet inter-site transfer is associated with lapses in care quality that adversely affect patient outcomes. A common iatrogenic harm precipitated at the time of transfer is harm from drug prescribing, or adverse drug events (ADEs). In this study we will evaluate a medication reconciliation tool developed to help providers make effective prescribing decisions at the time of transfer between VA sites of care (Improved Prescribing after Transfer (IPT)). We will evaluate the quantitative effectiveness of the tool in reducing transition drug risk and ADEs. We additionally will conduct focus group discussions and cognitive task analysis among end-users to better understand how providers make drug-prescribing decisions at the time of transfer and to assess factors influencing effective use of the tool.

Conditions

  • Hospitalization

Interventions

BEHAVIORAL

Physician-initiated medication reconciliation

Physician house staff performed and documented medication reconciliation after hospital admission with the assistance of a CPRS template

BEHAVIORAL

Pharmacist-initiated medication reconciliation

Pharmacist performed and documented medication reconciliation

Sponsors & Collaborators

Principal Investigators

  • Kenneth S Boockvar, MD MS · James J. Peters Veterans Affairs Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2006-03-31
Completion
2010-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00370916 on ClinicalTrials.gov